Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
1. Claims 93-117 are pending.
2. Applicant’s election without traverse of Group I, claims 93-112 and 116 in the reply filed on 07/02/26 is acknowledged.
3. Upon further consideration the prior art search has been extended to include non-elected claims of Group II. The restriction requirement set forth in the previous Office Action, mailed on 02/02/26 is hereby vacated.
Claims 93-117 read on a nucleic acid encoding an antibody and antibody that binds to CD30L under consideration in the instant application.
4. The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
5. The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
6. Claims 93-117 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117.
The Markush grouping of variant species of CTLA-4 binding proteins is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons:
It is known in the art that the amino acid residues that define the structure of the
complementarity determining regions (CDR) of an antibody are critical to the functional specificity and affinity of the antibody for the target antigen, such that the 3 CDRs of the heavy and light chains form the antigen-binding domain of the antibody paratope, where critical contacts with the antigen epitope occur during binding (for review see MacCallum et al., 1996). Further, it is known that the heavy chain CDR2 and CDR3 regions contain most of the residues that have a major contribution to the binding free energy of the antigen binding domain (Dondelinger et al., 2018; pg. 8, col. 1, para. 2 – col. 2, para. 1). The CDR3, in particular, is highly variable. The assembly of the variable regions from the V(D)J genes is such that, following the recombination mechanisms, the joined regions are part of CDR3. The CDR3 loops are often critical for antigen binding in Igs and appear to provide the principal peptide binding residues in TCRs as well. Structural analysis has demonstrated that one or both of the CDR3 loops of the Ig heavy or light chain are always involved in antigen contact (Rock et al., 1994). Thus, when assessing the functional identity of an antibody, or antigen binding protein, the length and amino acid sequences of the set of CDRs are a critical structural characteristic of the protein as a whole.
Regarding the “single structural similarity” of a proper Markush grouping, the alternatives must share a substantial structural feature from which the common use flows. In the case of the claimed nucleic acid encoding antibody and antibody thereof that binds to CD30L would flow from the CDRs, and in particular the CDR3 regions. Applicants present several alternative embodiments, each comprising a light chain CDR3 and a heavy chain CDR3, wherein there are various L-CDR3s and H-CDR3s. When comparing the sharedness of amino acid structure of the alternate CDR3 regions, it is clear they may be quite distinct. However, with a range of length from 9-16 total residues, and the amount of variability in residues from one variant to the next, it is difficult to assign even a basic shared structural similarity to all recited species, upon which variants may be generated. That is, a common base sequence structure from which techniques such as affinity maturation may be used to determine specific point mutations in order to generate variant embodiments.
Section 803.04 of the MPEP states that “sequences that encode different proteins are structurally distinct and are deemed to constitute distinct and independent inventions.” The claimed nucleic acid encoding antibody and antibody thereof that binds to CD30L are not all members of the same recognized physical or chemical class or the same art-recognized class, as the disclosed binding proteins are novel. Also, all claimed nucleic acid encoding antibody and antibody thereof that binds to CD30L described do not share a single structural similarity from which the common functionality of binding CD30L naturally flows, rather the critical H-CDR3 regions are structurally distinct from each other in amino acid sequence. Therefore, the claimed nucleic acid encoding antibody and antibody thereof that binds to CD30L are distinct species of binding proteins do no comprise a “proper” Markush grouping. The elected species of antibody comprising SEQ ID NOs 6,119,159,199,8,319,359 and 39 has been searched and found to be free of the prior art. As the alternative species of claims 93-117 are not a proper Markush grouping, the examiner has not extended the search beyond the elected species, as per MPEP section 803.03(III)(C)(2).
To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use.
7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
8. Claims 93-117 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-30 of U.S. Patent No. 11886,505.
Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-30 of US Patent ‘505 recited an antibody that binds to CD30L and comprises VH, comprising CDRH1-CDRH3 and VL, comprising CDRL1-CDL-3 that are 100% identical to the instantly claimed ( see sequence alignment).
9. Claims 93-117 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 12/516,126 and claims 1-8 of US Patent 12/305,236.
Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the instant Application are drawn nucleic acid encoding an antibody and antibody that binds to CD30L that are used in methods of inhibiting IL-8 release or CD30L binding to CD30 comprising administering antibody that binds to CD30L and comprises VH, comprising CDRH1-CDRH3 and VL, comprising CDRL1-CDL-3 that are 100% identical to the instantly claimed ( see sequence alignment). and wherein said antibody was disclosed in the specification of said Patents.
This rejection is necessitated by the decision of the Court of Appeals for the Federal Circuit in Pfizer Inc. v Teva pharmaceuticals USA Inc., 86 USPQ2d 1001, at page 1008 (March 2008), which indicates that there is no patentable distinction between claims to a product and a method of using that product disclosed in the specification of the application and that the preclusion of such a double patenting rejection under 35 USC 121 does not apply where the present application is other than a divisional application of the patent application containing such patentably indistinct claims.
9. The claims 93-117 are provisionally rejected on the grounds of nonstatutory double patenting of the claims of copending Applications No. 18/997,306,18/510,511,19/400372
Although the conflicting claims are not identical, they are not patentably distinct from each other because claims of copending Application No. 18/997,306,18/510,511,19/400372 each
recited an antibody that binds to CD30L and comprises VH, comprising CDRH1-CDRH3 and VL, comprising CDRL1-CDL-3 that are 100% identical to the instantly claimed ( see sequence alignment).
This is a provisional nonstatutory double patenting rejection because the conflicting claims have not in fact been patented.
10. No claim is allowed.
11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gregory Emch can be reached on 571/ 272-8149
The fax number for the organization where this application or proceeding is assigned is 571/273-8300
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/MICHAIL A BELYAVSKYI/Primary Examiner, Art Unit 1644